These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31609094)

  • 1. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
    Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK; Zhao P; Lu C; Luo J; Hu R
    Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
    Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
    Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
    Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
    Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of apocrine salivary duct carcinoma.
    Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
    Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
    Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
    Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
    Nardi V; Sadow PM; Juric D; Zhao D; Cosper AK; Bergethon K; Scialabba VL; Batten JM; Borger DR; Iafrate AJ; Heist RS; Lawrence DP; Flaherty KT; Bendell JC; Deschler D; Li Y; Wirth LJ; Dias-Santagata D
    Clin Cancer Res; 2013 Jan; 19(2):480-90. PubMed ID: 23186780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
    Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
    Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
    Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L; Williams MD; Bell D
    Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
    Ryu HJ; Koh YW; Yoon SO
    Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.
    Alame M; Cornillot E; Cacheux V; Tosato G; Four M; De Oliveira L; Gofflot S; Delvenne P; Turtoi E; Cabello-Aguilar S; Nishiyama M; Turtoi A; Costes-Martineau V; Colinge J
    Theranostics; 2020; 10(10):4383-4394. PubMed ID: 32292502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.